Literature DB >> 6296220

Portal, hepatic and peripheral insulin immunoreactive substances before and after removal of an insulinoma.

C Villaume, B Beck, J P Pointel, P Drouin, G Debry.   

Abstract

Plasma insulin immunoreactivity (IRI) results from high molecular weight substances with insulin immunoreactivity (HWIRI), proinsulin (PI) and insulin (I). Their respective concentrations and percentages of IRI were determined preoperatively in the hepatic and peripheral circulations and after surgery in the latter two and in the portal circulation in a patient with a pancreatic adenoma. Removal of the insulinoma resulted in a highly significant reduction of PI concentration in the hepatic (from 16.2 +/- 1.9 microU/ml to 7.3 +/- 0.8 microU/ml) and in the peripheral (from 24.0 +/- 2.0 microU/ml to 9.2 +/- 1.2 micro U/ml) venous systems. Similarly, I concentration decreased in the hepatic (from 36.9 +/- 3.4 microU/ml to 28.0 +/- 1.0 microU/ml) and peripheral (from 33.8 +/- 3.4 microU/ml to 19.8 +/- 2.0 microU/ml) venous systems. HWIRI concentration decreased in the hepatic venous system (from 6.9 +/- 0.8 microU/ml, to 4.8 +/- 0.6 microU/ml), but the decrease in the peripheral venous system (from 9.7 +/- 1.4 microU/ml to 8.2 +/- 1.2 microU/ml) was not significant. It was found that the concentration of I virtually was the same in hepatic and peripheral blood prior to operation in contrast to a decrease seen after the operation. This indicates that the hyperinsulinemia caused primarily by the autonomous hypersecretion of the insulinoma was amplified by a decreased degradation of insulin by the liver and kidney. Our results also indicate that HWIRI was found with the highest concentration in the peripheral blood independently of the adenoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296220     DOI: 10.1007/BF03350520

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Binding and degradation of 125I-insulin by rat hepatocytes.

Authors:  S Terris; D F Steiner
Journal:  J Biol Chem       Date:  1975-11-10       Impact factor: 5.157

2.  Immunoreactive insulin in portal and hepatic venous blood in patients with insuloma.

Authors:  M Eriksson; R Erwald; R Hed; A Nygren; J Patricny; S Röjdmark; L Sundblad; K L Wiechel
Journal:  Acta Med Scand       Date:  1976

Review 3.  Progress report. Diagnosis of insulinoma.

Authors:  V Marks
Journal:  Gut       Date:  1971-10       Impact factor: 23.059

4.  The handling of insulin, proinsulin, and C-peptide by the isolated rat kidney.

Authors:  R Rabkin; B D Ross; M E Mako; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

5.  High molecular weight substances with insulin immunoreactivity.

Authors:  C Villaume; B Beck; G Debry
Journal:  Diabete Metab       Date:  1979-06

6.  Existence in fetal and adult rat of several forms of material reacting with anti-insulin antibody (IRI).

Authors:  J M Felix; M T Sutter-Dub; C Legrele; B Billaudel
Journal:  Horm Metab Res       Date:  1975-07       Impact factor: 2.936

7.  Insulin in portal, hepatic and peripheral venous blood after glucose, tolbutamide and glipizide stimulation. Indication of insulin release from peripheral tissues.

Authors:  R Hed; A Nygren; R Röjdmark; L Sundblad; K L Wiechel
Journal:  Acta Med Scand       Date:  1979

8.  Elevation of C-peptide immunoreactivity in plasma of normal subjects after trypsin action.

Authors:  B Beck; C Villaume; G Debry
Journal:  Diabete Metab       Date:  1980-03

9.  Changes in the proportions of plasma insulin, proinsulin and a higher-molecular-weight insulin during pre- and post-operative glucose-infusion tests.

Authors:  D Mangnall; A E Giddings; H H Lafferty; R G Clark
Journal:  Clin Sci Mol Med       Date:  1977-12

10.  Studies on the different forms of material reacting with antiinsulin antibodies in the fetal and adult rat.

Authors:  J M Felix; M T Sutter-Dub; C Legrele
Journal:  Horm Metab Res       Date:  1975-09       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.